Last $9.37 USD
Change Today +0.245 / 2.69%
Volume 2.7M
MACK On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

merrimack pharmaceuticals in (MACK) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/24/14 - $9.45
52 Week Low
11/6/13 - $2.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

merrimack pharmaceuticals in (MACK) Related Bloomberg News

View More Bloomberg News

merrimack pharmaceuticals in (MACK) Related Businessweek News

No Related Businessweek News Found

merrimack pharmaceuticals in (MACK) Details

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company’s product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

254 Employees
Last Reported Date: 03/4/14
Founded in 1993

merrimack pharmaceuticals in (MACK) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $512.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Senior Vice President of Corporate Operations
Total Annual Compensation: $343.3K
Senior Vice President of Business Development...
Total Annual Compensation: $305.7K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $364.6K
Compensation as of Fiscal Year 2013.

merrimack pharmaceuticals in (MACK) Key Developments

Merrimack Pharmaceuticals Announces Additional Clinical and Biomarker Data from Phase 2 Study in ER/PR-Positive, HER2-Negative Metastatic Breast Cancer

Merrimack Pharmaceuticals, Inc. announced additional clinical and biomarker data from a Phase 2 study in ER/PR-positive, HER2-negative metastatic breast cancer showing that patients with high heregulin mRNA levels achieved a statistically significant benefit from combining the novel agent MM-121 with exemestane. Updated data from this biomarker subgroup, representing 45% of patients with metastatic breast cancer, showed a hazard ratio of 0.26 with a p-value of 0.003. The data were presented at the European Society of Medical Oncology (ESMO) 2014 Congress as part of a meta-analysis of the biomarker data from three Phase 2 studies of MM-121 in combination with standard-of-care agents across breast, lung and ovarian cancers. MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin. In Second Quarter 2014, Merrimack regained worldwide rights to MM-121 and is pursuing a partnership to support the continued development of the program. Previous results from the MM-121 Phase 2 program presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting identified high heregulin mRNA as prognostic of poor response to standard-of-care therapy across multiple cancers. These results also showed that patients with heregulin-high tumors experienced a reduction in their risk of progression when they received a combination of MM-121 with their standard-of-care therapy as compared to patients who received the standard therapy alone. The previous analysis included 55 patients with breast cancer, 17 of whom were biomarker positive. The poster presented at ESMO 2014 provides biomarker data on 76 ER/PR positive, HER2-negative patients with metastatic breast cancer, 34 of whom were biomarker positive (heregulin-high). The poster also provides the first cross-indication analysis of biomarker data from platinum-resistant ovarian cancer, ER/PR+ HER2- breast cancer and EGFR wild-type non-small cell lung cancer.

Merrimack Pharmaceuticals, Inc. Enters into License and Collaboration Agreement for the Development and Commercialization of Product Candidate MM-398

On September 23, 2014, Merrimack Pharmaceuticals, Inc. and Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA (collectively “Baxter”) entered into a License and Collaboration Agreement for the development and commercialization of Merrimack’s product candidate MM-398 outside of the United States and Taiwan. Under the Agreement, Merrimack granted Baxter an exclusive, royalty-bearing right and license under Merrimack’s patent rights and know-how to develop and commercialize MM-398 in the Licensed Territory. Baxter is responsible for using commercially reasonable efforts to develop, obtain regulatory approvals for and, following regulatory approval, commercialize MM-398 in the Licensed Territory, including in a specified number of specified major countries in each of Asia, Europe and the remainder of the Licensed Territory. Under the Agreement, Baxter will pay Merrimack a non-refundable fee of $100 million. In addition, Merrimack is eligible to receive from Baxter up to an aggregate of $100 million upon the achievement of specified research and development milestones, up to an aggregate of $520 million upon the achievement of specified regulatory milestones and up to an aggregate of $250 million upon the achievement of specified sales milestones. Merrimack and Baxter will share equally the cost of conducting all clinical trials contemplated by the global development plan, except that Merrimack will be responsible for the first $98.8 million of costs related to the development of MM-398 for pancreatic cancer patients who have not previously received gemcitabine.

Merrimack Pharmaceuticals, Inc. - Special Call

To review the details of the partnership of Baxter International Inc and Merrimack Pharmaceuticals, Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MACK:US $9.37 USD +0.245

MACK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MACK.
View Industry Companies

Industry Analysis


Industry Average

Valuation MACK Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRIMACK PHARMACEUTICALS IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at